Emerging risks due to new injecting patterns in Hungary during austerity times

Substance Use and Misuse

Volumn 50, Issue 7, 2015, Pages 848-858

  Tarján, Anna ^a   Dudás, Mária ^a   Gyarmathy, V Anna ^b   Rusvai, Erzsébet ^a   Tresó, Bálint ^a   Csohán, Ágnes ^a  

^a NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Economic recession; Harm reduction; Hepatitis C; Heroin shortage; Injecting drugs use; New psychoactive substances; Risk behaviors; Synthetic cathinones; Syringe sharing; Syringe exchange program

Indexed keywords

PSYCHOTROPIC AGENT;

COMORBIDITY; DRUG ABUSE; ECONOMIC RECESSION; HEPATITIS C; HUMAN; HUNGARY; PREVALENCE; SUBSTANCE ABUSE; TRENDS;

COMORBIDITY; ECONOMIC RECESSION; HEPATITIS C; HUMANS; HUNGARY; NEEDLE SHARING; PREVALENCE; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84951735664     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2015.978672     Document Type: Article

References (58)

1. Bajzáth, S., Tóth, E., Zs., & Rácz, J. (2014). Repülök a gyógyszerrel. A kábítószerezés története a szocialista Magyarországon. Budapest: L'Harmattan.
2. Botescu, A., Abagiu, A., Mardarescu, M., & Ursan, M. (2012). HIV/AIDS among injecting drug users in Romania. Report of a recent outbreak and initial response policies. Retrieved 10 December, 2013, from http://www.emcdda.europa. eu/publications/ad-hoc/2012/romania-hiv-update
3. Carhart-Harris, R. L., King, L. A., & Nutt, D. J. (2011). A web-based survey on mephedrone. Drug Alcohol Depend, 118(1), 19-22. doi: 10.1016/j.drugalcdep.2011.02.011
4. Corson, S., Greenhalgh, D., Taylor, A., Palmateer, N., Goldberg, D., & Hutchinson, S. (2013). Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. Drug Alcohol Depend, 133(1), 172-179. doi: 10.1016/j.drugalcdep.2013.05.014
5. Cox, J., Morissette, C., De, P., Tremblay, C., Allard, R., Graves, L., Roy, E. (2009). Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users. Subst Use Misuse, 44(4), 548-568. doi: 10.1080/10826080802544349
6. Csak, R., Demetrovics, Z., & Racz, J. (2013). Transition to injecting 3, 4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. J Psychopharmacol, 27(6), 559-563. doi: 10.1177/0269881113480987
7. Csak, R., Gyekiss, R., Marvanykovi, F., Vadasz, V., & Racz, J. (2010). Magyarországi intravénás mefedronhasználat a tucsere szolgáltatók tapasztalatai alapján. Addictologia Hungarica, IX(4), 281-288
8. Csesztregi, T. (2013). Black market on the basis of substances seized in Hungary (in Hungarian). (presentation). Retrieved December 13, 2013 http://drogfokuszpont.hu/wp-content/uploads/feketepiaci-helyzetkep csesztregi drdews forensic 2013.pdf
9. Davies, S., Wood, D. M., Smith, G., Button, J., Ramsey, J., Archer, R., Dargan, P. I. (2010). Purchasing 'legal highs' on the Internet-is there consistency in what you get? QJM, 103(7), 489-493. doi: 10.1093/qjmed/hcq056
10. Dybdal-Hargreaves, N. F., Holder, N. D., Ottoson, P. E., Sweeney, M. D., & Williams, T. (2013). Mephedrone: Public health risk, mechanisms of action, and behavioral effects. Eur J Pharmacol, 714(1-3), 32-40. doi: 10.1016/j.ejphar.2013.05.024
11. ECDC, & EMCDDA. (2011). Prevention and control of infectious diseases among people who inject drugs Stockholm: ECDC.
12. EHRN. (2009). Young people and injecting drug use in selected countries of Central and Eastern Europe. Vilnius: EHRN.
13. EMCDDA. (2004). Hepatitis C and injecting drug use: impact, costs and policy options. Lisbon: EMCDDA.
14. EMCDDA. (2006). Protocol for the implementation of the EMCDDA key indicator drug related infectious diseases (DRID), draft version 6 October 2006. EMCDDA. Lisbon. Retrieved from http://drogfokuszpont.hu/wp-content/uploads/drid protocol 2006.pdf
15. EMCDDA. (2012a). Country Profle-Hungary. Country legal profles Retrieved 26 May, 2014, from http://www.emcdda. europa.eu/html.cfm/index5174EN.html#
16. EMCDDA. (2012b). Synthetic cathinones. Drug profles Retrieved 25 May, 2014, from http://www.emcdda.europa.eu/publications/drug-profles/synthetic-cathinones
17. EMCDDA. (2013a). European Drugs Report 2013. Lisbon: EM-CDDA.
18. EMCDDA. (2013b). Perspectives on drugs. Trends in heroin use in Europe: what do treatment demand data tell us? Retrieved from http://www.emcdda.europa.eu/topics/pods/trends-in-heroin-use
19. EMCDDA. (2013c). Standard Stable 9. Retrieved December 13, 2013, from EMCDDA http://www.emcdda.europa. eu/themes/key-indicators/drid
20. EMCDDA. (2013d). Statistical Bulletin 2013. Retrieved December 13, 2013, from EMCDDA http://www.emcdda.europa.eu/stats13
21. EMCDDA. (2014). Injection of synthetic cathinones. Perspectives on drugs Retrieved from http://www.emcdda.europa. eu/attachements.cfm/att 228233 EN POD2014 Injection%20 of%20synthetic%20cathinones.pdf
22. EMCDDA, & ECDC. (2012). Joint EMCDDA and ECDC rapid risk assessment: HIV in Injecting Drug Users in the EU/EEA, following a reported increase of cases in Greece and Romania. Retrieved from http://www.emcdda.europa.eu/publications/joint-publications/hiv-in-injecting-drug-users-2011 doi:10.2810/50417
23. EMCDDA, & Europol. (2013). New drugs in Europe, 2012. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA. Luxembourg: Publications Offce of the European Union.
24. Fotiou, A., Micha, K., Paraskevis, D., Terzidou, M., Malliori, M., & Hatzakis, A. (2012). HIV outbreak among injecting drug users in Greece. An Updated brief report for the EMCDDA on the recent outbreak of HIV infections among drug injectors in Greece. Retrieved from http://www.emcdda.europa.eu/publications/ad-hoc/2012/greece-hiv-update
25. Friedman, S. R., Rossi, D., & Braine, N. (2009). Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy, 20(3), 283-291. doi: 10.1016/j.drugpo.2008.10.006
26. Friedman, S., Rossi, D., & Flom, P. L. (2006). "Big Events" and Networks. Connect (Tor), 27(1), 9-14.
27. Griffths, P., Mounteney, J., & Laniel, L. (2012). Understanding changes in heroin availability in Europe over time: emerging evidence for a slide, a squeeze and a shock. Addiction, 107(9), 1539-1540. doi: 10.1111/j.1360-0443.2012.03829.x
28. Gyarmathy, V. A., Caplinskiene, I., Caplinskas, S., & Latkin, C. A. (2014). Social network structure and HIV infection among injecting drug users in Lithuania: gatekeepers as bridges of infection. AIDS Behav, 18(3), 505-510. doi: 10.1007/s10461-014-0702-6
29. Gyarmathy, V. A., Neaigus, A., Li, N., Ujhelyi, E., Caplinskiene, I., Caplinskas, S., & Latkin, C. A. (2010). Liquid drugs and high dead space syringes may keep HIV and HCV prevalence high-A comparison of Hungary and Lithuania. Eur Addict Res, 16(4), 220-228. doi: 10.1159/000320287
30. Gyarmathy, V. A., Neaigus, A., Mitchell, M. M., & Ujhe-lyi, E. (2009). The association of syringe type and syringe cleaning with HCV infection among IDUs in Budapest, Hungary. Drug Alcohol Depend, 100(3), 240-247. doi: 10.1016/j.drugalcdep.2008.10.014
31. Gyarmathy, V. A., Neaigus, A., & Ujhelyi, E. (2009). Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary. Eur J Public Health, 19(3), 260-265. doi: 10.1093/eurpub/ckp009
32. Gyarmathy, V. A., & Racz, J. (2010). [Epidemiology of hepatitis C and human immunodefciency virus infections among injecting drug users in Hungary-what's next?]. Orv Hetil, 151(10), 365-371. doi: 10.1556/oh.2010.28821
33. Hedrich, D., Kalamara, E., Sfetcu, O., Pharris, A., Noor, A., Wiessing, L., Van de Laar, M. (2013). Human immunodefciency virus among people who inject drugs: Is risk increasing in Europe? Euro Surveill, 18(48).
34. Hill, A. B. (1965). THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med, 58, 295-300.
35. Hillebrand, J., Olszewski, D., & Sedefov, R. (2010). Legal highs on the Internet. Subst Use Misuse, 45(3), 330-340. doi: 10.3109/10826080903443628
36. HNFP. (2010). 2010 National Report to the EMCDDA. Retrieved December 13, 2013, from HNFP http://drogfokuszpont.hu/wp-content/uploads/nr10en.pdf
37. HNFP. (2011). 2011 National Report to the EMCDDA. Retrieved December 13, 2013, from HNFP http://drogfokuszpont.hu/wp-content/uploads/nationalreport2011hungary.pdf
38. HNFP. (2012). 2012 National Report to the EMCDDA. Retrieved December 13, 2013 http://drogfokuszpont.hu/wp-content/uploads/HUNationalReport2012.pdf
39. HNFP. (2013). 2013 National Report to the EMCDDA. Retrieved December 2013, 2013 http://drogfokuszpont.hu/wp-content/uploads/HUNationalReport2013.pdf
40. Kentikelenis, A., Karanikolos, M., Papanicolas, I., Basu, S., Mc-Kee, M., & Stuckler, D. (2011). Health effects of fnancial crisis: omens of a Greek tragedy. Lancet, 378(9801), 1457-1458. doi: 10.1016/s0140-6736(11)61556-0
41. NCE. (2013). Epinfo, 47. Retrieved from http://www.oek.hu/oek.web?to=839&nid=41&pid=14&lang=hun
42. Paraskevis, D., Nikolopoulos, G., Fotiou, A., Tsiara, C., Paraskeva, D., Sypsa, V., Hatzakis, A. (2013). Economic Recession and Emergence of an HIV-1 Outbreak among Drug Injectors in Athens Metropolitan Area: A Longitudinal Study. PLoS One, 8(11), e78941. doi: 10.1371/journal.pone.0078941
43. Péterf, A., Tarján, A., Horváth, G., Csesztregi, T., & Nyírády, A. (2014). Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Analysis, 6(7-8), 825-831. doi: 10.1002/dta.1625
44. Pharris, A., Wiessing, L., Sfetcu, O., Hedrich, D., Botescu, A., Fo-tiou, A., van de Laar, M. J. (2011). Human immunodefciency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill, 16(48), pii=20032.
45. Racz, J., Csak, R., Farago, R., & Vadasz, V. (2012). [The phenomenon of drug change in the interviews with injecting drug users]. Psychiatr Hung, 27(1), 29-47.
46. Rhodes, T. (2009). Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy, 20(3), 193-201. doi: 10.1016/j.drugpo.2008.10.003
47. Szily, E., & Bitter, I. (2013). Designer drugs in psychiatric practice-A review of the literature and the recent situation in Hungary. Neuropsychopharmacol Hung, 15(4), 223-231.
48. Ta r j án, A. (2012a). Changes and risks due to new injecting patterns in Hungary. Paper presented at the EU expert meeting on DRID, Lisbon.
49. Ta r j án, A. (2012b). National syringe and client turnover data. report (restricted availability). HNFP.
50. Ta r j án, A. (2013). National syringe and client turnover data. report (restricted availability). HNFP, Budapest.
51. Treso, B., Takacs, M., Dencs, A., Dudas, M., Par, A., & Rusvai, E. (2013). Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill, 18(47).
52. Turner, K. M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., Hickman, M. (2011). The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction, 106(11), 1978-1988. doi: 10.1111/j.1360-0443.2011.03515.x
53. UNODC. (2013). World drug report 2013. Vienna: EMCDDA.
54. Van Hout, M. C., & Bingham, T. (2012). "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy, 23(3), 188-197. doi: 10.1016/j.drugpo.2012.01.008
55. Vickerman, P., Hickman, M., May, M., Kretzschmar, M., & Wiessing, L. (2010). Can hepatitis C virus prevalence be used as a measure of injection-related human immunodefciency virus risk in populations of injecting drug users? An ecological analysis. Addiction, 105(2), 311-318. doi: 10.1111/j.1360-0443.2009.02759.x
56. Vickerman, P., Hickman, M., Rhodes, T., & Watts, C. (2006). Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defc Syndr, 42(3), 355-361. doi: 10.1097/01.qai.0000219788.73539.47
57. Vickerman, P., Martin, N., Turner, K., & Hickman, M. (2012). Can needle and syringe programs and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction, 107(11), 1984-1995. doi: 10.1111/j.1360-0443.2012.03932.x
58. WHO, UNODC, & UNAIDS. (2013). Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users (2012 revision ed.). Geneva: WHO.